Clinical usefulness of prognostic biomarkers in optic neuritis. (6th February 2018)

• Record Type: Journal Article
• Authors: Tejeda‐Velarde, A.; Costa‐Frossard, L.; Sainz de la Maza, S.; Carrasco, Á.; Espiño, M.; Picón, C.; Toboso, I.; Walo, P. E.; Lourido, D.; Muriel, A.; Álvarez‐Cermeño, J. C.; Villar, L. M.
• Is Part Of: European journal of neurology. Volume 25:Number 4(2018)
• Page Start: 614
• Page End: 618
• Publication Date: 2018-02-06
• Subjects: antibodies -- demyelinating diseases -- multiple sclerosis -- optic neuritis; Neurology -- Periodicals; Nervous system -- Diseases -- Periodicals; 616.8
• DOI: 10.1111/ene.13553
• Languages: English
• ISSNs: 1351-5101

Abstract

Abstract : Background and purpose: Different biological and radiological biomarkers predict clinical conversion to multiple sclerosis (MS) after a clinically isolated syndrome (CIS). The aim was to explore their role in predicting the outcome of patients with optic neuritis (ON), a CIS considered to have a benign prognosis. Methods: Sixty‐eight consecutive ON patients were followed prospectively. Magnetic resonance imaging (MRI) and cerebrospinal fluid studies including oligoclonal immunoglobulin G (IgG) bands (OCGBs), lipid‐specific oligoclonal IgM bands (LS‐OCMBs) and neurofilament light chain quantification were performed at disease onset. Conversion to clinically definite MS (CDMS) was monitored. Results: The mean time of follow‐up of our series was 46.4 months. Twenty‐five patients (36.7%) developed CDMS during follow‐up. Neurofilament light chain levels did not predict clinical conversion. By contrast, an abnormal MRI increased the risk of CDMS [hazard ratio (HR) 12.5, P = 0.013]. The clearest association was found in patients with more than three T2 lesions. OCGBs also predicted the onset of CDMS (HR 21.3, P = 0.003) and LS‐OCMBs were associated with a shorter time to CDMS (HR = 116.6, P < 0.001). Conclusions: Magnetic resonance imaging and OCGBs predicted conversion to CDMS after an ON episode. In addition, LS‐OCMBs identified the ON patients more likely to develop MS early. These results, applicable to the everyday clinical setting, may be of interest for therapeutic decisions. Abstract : Clickhere for the corresponding questions to this CME article.